EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The Application of PD ‐1 Inhibitors in Immunotherapy for Glioblastoma

Ming-Zhen Dong, Ming Cui, Lin-Zhuo Qu, Hui-Ying Che, Hong-Jian Guan iD

The FASEB Journal · 28.02.2026 · 40 (4)

DOI: 10.1096/fj.202502901r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 14.02.2026. Verfasst von Ming-Zhen Dong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Yanbian University Hospital, Yanji, China. Hauptthemen laut MEDLINE: Glioblastoma, Immune Checkpoint Inhibitors, Immunotherapy, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Project of Provincial Department of Education, Research Fund of Yanbian University, Changbai Elite Talent Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common primary malignant brain tumor of the central nervous system, marked by drug resistance, rapid progression, and extremely low survival. Immunotherapy for this disease represents a new generation of treatment following surgery, chemotherapy, and radiotherapy. The emergence of immunotherapy has significantly advanced the treatment of various solid tumors and demonstrated promising efficacy. Although PD‐1 inhibitors show potential against GBM, clinical benefit from monotherapy remains modest. A series of clinical studies have found that combining PD‐1 inhibitors with chemotherapy, radiotherapy, oncolytic viruses, vaccines, other immune checkpoint inhibitors, and CAR‐T cell therapy shows better efficacy and safety, making it an attractive therapeutic approach. In this review, we provide a summary of the approved PD‐1 inhibitors in GBM, covering their use as monotherapy and in combination therapies, along with their prospects and the latest research advances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorBrain NeoplasmsHumansAnimals

Stichwörter der Autor:innen

CAR‐T cell therapyPD‐1 inhibitorsglioblastomaimmune checkpoint inhibitor

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Neurology Department, Yanbian University Hospital, Yanji, China.
  • Reproductive Medicine Center, Yanbian University Hospital, Yanji, China.
  • Department of General Practice, Yanbian University Hospital, Yanji, China.

ORCID-Profile: Hong-Jian Guan

Förderung

  • Research Project of Provincial Department of Education
  • Research Fund of Yanbian University
  • Changbai Elite Talent Program

Zitieren

APA

Dong, M. Z., Cui, M., Qu, L. Z., Che, H. Y., & Guan, H. J. (2026). The Application of PD ‐1 Inhibitors in Immunotherapy for Glioblastoma. The FASEB Journal, 40(4). https://doi.org/10.1096/fj.202502901r

Vancouver

Dong MZ, Cui M, Qu LZ, Che HY, Guan HJ. The Application of PD ‐1 Inhibitors in Immunotherapy for Glioblastoma. The FASEB Journal. 2026;40(4). doi:10.1096/fj.202502901r

BibTeX
@article{Dong2026,
  author = {Dong, Ming-Zhen and Cui, Ming and Qu, Lin-Zhuo and Che, Hui-Ying and Guan, Hong-Jian},
  title = {The Application of PD ‐1 Inhibitors in Immunotherapy for Glioblastoma},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {4},
  doi = {10.1096/fj.202502901r}
}
Kostenlos starten →